Sporadic early-onset Alzheimer’s disease (EOAD) is rare and understudied

Getty Images


October 19, 2023 — Alexandra Touroutoglou, PhD, and Bradford Dickerson, MD, neuroscientists in the department of Neurology at Massachusetts General Hospital, are the lead authors of a new study published in Alzheimer’s & Dementia, The Sporadic Early-onset Alzheimer’s Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cohort.  

What Question Were You Investigating? 

Is there a signature biomarker for younger/early-onset Alzheimer’s Disease (EOAD)? 

Sporadic early-onset Alzheimer’s disease (EOAD) is rare and understudied. However, it is known to be a devastating form of Alzheimer’s disease (AD) affecting patients often in their 40s and 50s at the peak of their productive life, when they may be balancing careers, family responsibilities and community roles. 

Previous neuroimaging studies have advanced our understanding of neurodegeneration in sporadic EOAD. Still, these studies have included small samples and have not focused on developing an MRI biomarker. 

This study defined an EOAD-signature MRI biomarker using data from a well-characterized discovery sample from Massachusetts General Hospital (MGH) and tested the hypothesis that it can be reproducible in a large validation sample of participants with EOAD. 

What Methods or Approached Did You Use? 

We obtained the data from two independent cohorts. The MGH EOAD cohort included 25 patients in the ongoing MGH Frontotemporal Disorders Unit Longitudinal Cohort. The second cohort included 211 patients enrolled in the 18-site multicenter Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) consortium, a collaboration led by Liana Apostolova, MD at Indiana University School of Medicine, Indianapolis, Brad Dickerson, MD of Massachusetts General Hospital, Boston, Gil Rabinovici, MD at the University of California, San Francisco, and Maria Carrillo, PhD of the Alzheimer’s Association. 

LEADS participants receive a standard clinical evaluation and Magnetic Resonance Imaging (MRI) scanning as well as amyloid and tau PET scanning and fluid biomarker assessments on an annual basis. 

What Were Your Findings? 

Using quantitative analysis of brain atrophy from MRI scans, we identified a signature pattern of distributed cortical atrophy in EOAD that replicated across two well-characterized independent samples: a discovery sample of 25 participants with EOAD from MGH and a large validation sample of 211 participants with EOAD from the multicenter LEADS consortium. 

In addition to reliability across the two samples, the EOAD signature demonstrated clinical validity against widely used measures of symptom severity and cognitive function, with greater atrophy associated with greater cognitive impairment. 

The EOAD signature accurately differentiated EOAD patients from healthy controls as well as patients with early-onset non AD conditions associated with cognitive impairment. 

What Are the Clinical Implications? 

We were able to prove that the EOAD signature is a clinically valid measure of AD-related neurodegeneration. 

Future work will focus on using the EOAD signature of regional atrophy to examine changes in the brains of patients over time. 

Follow-up studies will also explore the relationship between atrophy within the EOAD signature and impairments in different cognitive domains. 

For more information: https://www.massgeneral.org/ 

 

Paper Cited:

Touroutoglou et al. (2023). The Sporadic Early-onset Alzheimer’s Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cohort. Alzheimer’s Dement. 2023;1–15. Alzheimer's & Dementia: The Journal of the Alzheimer's Association.   

 

Related Alzheimer's Content:    

Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders    

FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm    

VIDEO: Researchers Use MRI to Predict Alzheimer's Disease    

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer's Patients    

Good Results for Alzheimer’s Imaging Agent    

NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers    

Alzheimer’s Association Launches New Website for IDEAS Study    

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment    

Impaired Glymphatic System May be Linked with Progression of Alzheimer's Disease, Finds New Study  

Radiologists Must Monitor Novel Alzheimer’s Treatment Side Effect 


Related Content

News | Magnetic Resonance Imaging (MRI)

November 30, 2023 — Royal Philips, a global leader in health technology, today launched three new fit for purpose MR ...

Time November 30, 2023
arrow
News | Radiology Imaging

November 30, 2023 — Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the ...

Time November 30, 2023
arrow
News | Pediatric Imaging

November 30, 2023 — Youth baseball players are prone to elbow pain and injuries, including repetitive overuse changes ...

Time November 30, 2023
arrow
News | Contrast Media

November 29, 2023 — Bayer continues to advance its comprehensive Radiology portfolio with progress in the development ...

Time November 29, 2023
arrow
News | Pediatric Imaging

November 29, 2023 — Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and ...

Time November 29, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

November 29, 2023 — Researchers have identified objective evidence of how the neck muscles are involved in primary ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 28, 2023 — Combining Vista.ai's leading radiology AI-guided software that automates MRI exams for quick and ...

Time November 28, 2023
arrow
News | Digital Radiography (DR)

November 28, 2023 — Canon Medical Components USA (CMCU) - Digital Radiography (DR), global leaders in advanced flat ...

Time November 28, 2023
arrow
News | RSNA

November 28, 2023 — New research being presented this week at the annual meeting of the Radiological Society of North ...

Time November 28, 2023
arrow
News | Computed Tomography (CT)

November 28, 2023 — Smoking marijuana in combination with cigarettes may lead to increased damage of the lung’s air sacs ...

Time November 28, 2023
arrow
Subscribe Now